
Chinese pharmaceutical company headquartered in Hangzhou, Zhejiang and listed on the Shenzhen Stock Exchange ChiNext board under code 300558, focused on innovative small molecule medicines for cancer. Best known for icotinib, the first domestically developed EGFR tyrosine kinase inhibitor approved in China, and its portfolio also includes ensartinib for ALK positive lung cancer, vorolanib and befotertinib, supported by research centres in Hangzhou and Beijing and international collaborations.
留下您的评分